StudyManager Evolve Gaining Momentum in Chinese Market
StudyManager announced that GCP ClinPlus Ltd and Chongqing Jiachen Biotechnology have deployed StudyManager’s Evolve software to manage their latest clinical studies.
Both deployments represent significant milestones for StudyManager, which began its expansion into China in early 2009. Demand for StudyManager Evolve, the company’s sponsor/CRO-focused product, has gained traction internationally following the success of numerous clinical trials and increased market share in the United States.
“We spent more than a year evaluating EDC systems that include both US. and Chinese vendors’ products,” said Dr. Ivan Zhai, CEO of GCP ClinPlus Ltd. “We selected Evolve as our EDC system because it is a simple, easy-to-use system that our sites are excited to use, with minimal user training. This should improve data entry compliance and data quality right from the start, while maintaining happy site users.”
Chongqing Jiachen Biotechnology Ltd. found Evolve to be flexible and easy to use—an ideal solution for managing data on behalf of the small- to mid-size biotechnology and pharmaceutical companies for which Chongqing Jiachen manages clinical trials.
Evolve's web-based interface integrates clinical trial management and electronic data capture tools. These features are highly scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
